These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 25526223)
21. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405 [TBL] [Abstract][Full Text] [Related]
22. 2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition. Nepali K; Kumar S; Huang HL; Kuo FC; Lee CH; Kuo CC; Yeh TK; Li YH; Chang JY; Liou JP; Lee HY Org Biomol Chem; 2016 Jan; 14(2):716-723. PubMed ID: 26694589 [TBL] [Abstract][Full Text] [Related]
23. Inhibition and function of heat shock proteins 70 and 90. Blagg BS Curr Top Med Chem; 2009; 9(15):1335-6. PubMed ID: 19925436 [No Abstract] [Full Text] [Related]
24. Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening. Sun HP; Jia JM; Jiang F; Xu XL; Liu F; Guo XK; Cherfaoui B; Huang HZ; Pan Y; You QD Eur J Med Chem; 2014 May; 79():399-412. PubMed ID: 24763261 [TBL] [Abstract][Full Text] [Related]
25. Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors. Shevtsov M; Multhoff G; Mikhaylova E; Shibata A; Guzhova I; Margulis B Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31652993 [TBL] [Abstract][Full Text] [Related]
26. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351 [TBL] [Abstract][Full Text] [Related]
27. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells. Tung CL; Jian YJ; Syu JJ; Wang TJ; Chang PY; Chen CY; Jian YT; Lin YW Exp Cell Res; 2015 May; 334(1):126-35. PubMed ID: 25662161 [TBL] [Abstract][Full Text] [Related]
28. HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms. Sevin M; Girodon F; Garrido C; de Thonel A Mediators Inflamm; 2015; 2015():970242. PubMed ID: 26549943 [TBL] [Abstract][Full Text] [Related]
29. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors. Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Schwock J; Pham NA; Cao MP; Hedley DW Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866 [TBL] [Abstract][Full Text] [Related]
31. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma. Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840 [TBL] [Abstract][Full Text] [Related]
32. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781 [TBL] [Abstract][Full Text] [Related]
33. A chemical-biological study reveals C9-type iridoids as novel heat shock protein 90 (Hsp90) inhibitors. Dal Piaz F; Vassallo A; Temraz A; Cotugno R; Belisario MA; Bifulco G; Chini MG; Pisano C; De Tommasi N; Braca A J Med Chem; 2013 Feb; 56(4):1583-95. PubMed ID: 23362862 [TBL] [Abstract][Full Text] [Related]
34. Synthetic Small Molecule Modulators of Hsp70 and Hsp40 Chaperones as Promising Anticancer Agents. Nitzsche B; Höpfner M; Biersack B Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835501 [TBL] [Abstract][Full Text] [Related]
35. ATPases as drug targets: insights from heat shock proteins 70 and 90. Massey AJ J Med Chem; 2010 Oct; 53(20):7280-6. PubMed ID: 20608738 [No Abstract] [Full Text] [Related]
36. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709 [TBL] [Abstract][Full Text] [Related]
37. Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents. Kim HS; Hoang VH; Hong M; Chul Kim K; Ann J; Nguyen CT; Seo JH; Choi H; Yong Kim J; Kim KW; Sub Byun W; Lee S; Lee S; Suh YG; Chen J; Park HJ; Cho TM; Kim JY; Seo JH; Lee J Bioorg Med Chem; 2019 Apr; 27(7):1370-1381. PubMed ID: 30827868 [TBL] [Abstract][Full Text] [Related]
38. The protective role of HSP90 against 3-hydroxykynurenine-induced neuronal apoptosis. Lee MW; Park SC; Chae HS; Bach JH; Lee HJ; Lee SH; Kang YK; Kim KY; Lee WB; Kim SS Biochem Biophys Res Commun; 2001 Jun; 284(2):261-7. PubMed ID: 11394871 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796 [TBL] [Abstract][Full Text] [Related]
40. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective. Kumalo HM; Bhakat S; Soliman ME Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]